Sleep apnea clinical trials are one of the most active areas in sleep medicine. Obstructive sleep apnea (OSA) affects an estimated 936 million adults globally, and sponsors now have a broader toolkit than ever — GLP-1s with weight-loss-mediated AHI reduction, hypoglossal nerve stimulation devices, next-gen PAP hardware, and digital therapeutics for adherence. This guide covers how modern sleep apnea clinical trials are designed, recruited, and executed.
Endpoints that matter to reviewers
The apnea-hypopnea index (AHI) remains the primary endpoint for most OSA registrational programs, but reviewers increasingly expect supporting evidence across the full patient experience:
- AHI and ODI from polysomnography (PSG) or a validated home sleep apnea test (HSAT).
- PAP adherence — mean nightly use, ≥4h nights, and 30/90-day compliance.
- Patient-reported outcomes — ESS, FOSQ-10, PROMIS Sleep Disturbance.
- Cardiometabolic biomarkers — blood pressure, HbA1c, weight for GLP-1 combination studies.
In-lab PSG vs. home sleep apnea testing
FDA and EMA now accept HSAT-derived endpoints for many OSA programs when devices are validated and scoring is centralized. Sponsors moving to decentralized designs cut per-patient cost 40-60% versus in-lab PSG, at the price of tighter QC on device deployment and scoring. Our sleep research CRO team runs both models and helps sponsors pick the right one for the protocol's regulatory pathway.
Recruiting an OSA population
OSA is common but under-diagnosed — most sponsors budget too little for pre-screening. Effective sleep patient recruitment stacks three channels: specialty sleep-center site networks, primary-care referrals with STOP-BANG pre-screen, and digital funnels that route interested patients through a validated HSAT before randomization.
Devices and wearables in modern OSA trials
Hypoglossal nerve stimulation, oral appliances, and wearable positional therapy all require rigorous validation. Sponsors developing connected devices should read our medical device CRO and wearable clinical trials overviews for endpoint and human-factors guidance.
Timelines
A typical Phase 2 OSA study of 150-250 participants runs 12-18 months from site activation to database lock when HSAT is the primary endpoint modality. Adding in-lab PSG substudies extends the timeline 4-6 months but strengthens the submission package.